Drug Discovery and Development Solutions for Lung Cancer

Our In Vitro Efficacy Testing Service accelerates lung cancer drug discovery by providing robust screening and characterization of candidate compounds against critical targets such as EGFR, ALK, KRAS, and more. Utilizing advanced biochemical, cell-based, and biophysical assays—including ATP, chemiluminescent, flow cytometry, and surface plasmon resonance methods—we deliver precise measurements of IC-50, Kd, and pKi. Our comprehensive approach enables rapid assessment of compound potency, selectivity, and mechanism of action, supporting data-driven optimization. We empower researchers to identify and advance promising lung cancer therapies with confidence through sensitive, reliable, and high-throughput in vitro platforms.

Alfa Cytology provides comprehensive in vivo lung cancer animal model development services to accelerate preclinical drug discovery. Utilizing chemically-induced, genetically engineered, and xenograft (including PDX) models in various rodent strains, we ensure translational relevance and scientific rigor. Our end-to-end solutions cover model selection, induction, dosing, monitoring, and advanced endpoint analyses such as imaging, histopathology, and molecular profiling. With robust quality control, ethical compliance, and expert support, we deliver high-quality, reliable data. Partner with Alfa Cytology to leverage state-of-the-art capabilities and tailored approaches that empower your lung cancer research and therapeutic development objectives.

Our PK/PD research service for Lung Cancer offers comprehensive support for preclinical and translational drug development. We employ advanced analytical methods such as HPLC-MS and ELISA, and assess multiple administration routes including oral and intravenous. Our expertise spans compartmental analysis across plasma, tissues, and tumor microenvironments using validated animal models from mice to non-human primates. These capabilities enable detailed ADME profiling, concentration-effect modeling, and rational dosing optimization. By integrating robust data and translational insights, we accelerate candidate selection, regulatory submissions, and the development of effective, safe Lung Cancer therapeutics for our partners.

Alfa Cytology delivers comprehensive in vivo toxicity assessment services for lung cancer drug development, utilizing advanced methodologies and diverse animal models to ensure robust safety profiling. Key capabilities include acute, chronic, and organ-specific toxicity studies, neurotoxicity, reproductive, hematotoxicity, and systemic evaluations. Employing high-throughput histopathology, automated clinical chemistry, and digital behavioral analysis, all studies adhere to international regulatory standards. Specialized respiratory monitoring and inhalation delivery systems enhance translational relevance. Alfa Cytology’s integrated, data-driven approach empowers clients to make informed decisions, accelerates clinical progress, and ensures the safety and success of novel lung cancer therapeutics.

Alfa Cytology offers biomarker analysis services for Lung Cancer research, emphasizing the exploration of molecular candidates with potential as biomarkers. Utilizing advanced multi-omics approaches—including genomics, transcriptomics, proteomics, and metabolomics—we investigate disease mechanisms and assess candidate targets. Our screening and evaluation methodologies employ diverse analytical platforms such as immunoassays, mass spectrometry, flow cytometry, and molecular diagnostics. We prioritize rigorous assay development, reproducibility, and data quality throughout the research process. All investigations are conducted in preclinical contexts, supporting the rational evaluation of biomarker candidates while maintaining scientific objectivity and acknowledging the exploratory nature of biomarker research.